<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Hum Vaccin Immunother</journal-id>
<journal-id journal-id-type="iso-abbrev">Hum Vaccin Immunother</journal-id>
<journal-id journal-id-type="publisher-id">KHVI</journal-id>
<journal-id journal-id-type="publisher-id">khvi20</journal-id>
<journal-title-group>
<journal-title>Human Vaccines &amp; Immunotherapeutics</journal-title>
</journal-title-group>
<issn pub-type="ppub">2164-5515</issn>
<issn pub-type="epub">2164-554X</issn>
<publisher>
<publisher-name>Taylor &amp; Francis</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30735463</article-id>
<article-id pub-id-type="pmc">6605860</article-id>
<article-id pub-id-type="publisher-id">1571893</article-id>
<article-id pub-id-type="doi">10.1080/21645515.2019.1571893</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Commentary</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy</article-title>
<alt-title alt-title-type="running-authors">J. SALAS-MCKEE ET AL.</alt-title>
<alt-title alt-title-type="running-title">HUMAN VACCINES &amp; IMMUNOTHERAPEUTICS</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Salas-Mckee</surname>
<given-names>January</given-names>
</name>
<xref ref-type="aff" rid="AFF0001">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kong</surname>
<given-names>Weimin</given-names>
</name>
<xref ref-type="aff" rid="AFF0001">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gladney</surname>
<given-names>Whitney L.</given-names>
</name>
<xref ref-type="aff" rid="AFF0001">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jadlowsky</surname>
<given-names>Julie K.</given-names>
</name>
<xref ref-type="aff" rid="AFF0001">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Plesa</surname>
<given-names>Gabriela</given-names>
</name>
<xref ref-type="aff" rid="AFF0001">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Davis</surname>
<given-names>Megan M.</given-names>
</name>
<xref ref-type="aff" rid="AFF0001">
<sup>a</sup>
</xref>
<xref ref-type="aff" rid="AFF0002">
<sup>b</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fraietta</surname>
<given-names>Joseph A.</given-names>
</name>
<xref ref-type="corresp" rid="AN0001"></xref>
<xref ref-type="aff" rid="AFF0001">
<sup>a</sup>
</xref>
<xref ref-type="aff" rid="AFF0002">
<sup>b</sup>
</xref>
<xref ref-type="aff" rid="AFF0003">
<sup>c</sup>
</xref>
<xref ref-type="aff" rid="AFF0004">
<sup>d</sup>
</xref>
</contrib>
<aff id="AFF0001"><label>a</label><institution>Center for Cellular Immunotherapies, Abramson Cancer Center, University of Pennsylvania</institution>, Philadelphia, PA, <country>USA</country></aff>
<aff id="AFF0002"><label>b</label><institution>Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania</institution>, Philadelphia, PA, <country>USA</country></aff>
<aff id="AFF0003"><label>c</label><institution>Parker Institute for Cancer Immunotherapy, University of Pennsylvania</institution>, Philadelphia, PA, <country>USA</country></aff>
<aff id="AFF0004"><label>d</label><institution>Department of Microbiology, Perelman School of Medicine, University of Pennsylvania</institution>, Philadelphia, PA, <country>USA</country></aff>
</contrib-group>
<author-notes>
<corresp id="AN0001">CONTACT Joseph A. Fraietta <email xlink:href="jfrai@upenn.edu">jfrai@upenn.edu</email><institution>South Pavilion Expansion</institution>, <addr-line>Room 9-104 3400 Civic Center Blvd., Bldg. 421</addr-line>, Philadelphia, PA 19104, <country>USA</country>.</corresp>
</author-notes>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>2</day>
<month>4</month>
<year>2019</year>
</pub-date>
<volume>15</volume>
<issue>5</issue>
<fpage seq="18">1126</fpage>
<lpage>1132</lpage>
<history>
<date date-type="received">
<day>14</day>
<month>12</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>7</day>
<month>1</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Â© 2019 Taylor &amp; Francis Group, LLC</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>Taylor &amp; Francis</copyright-holder>
</permissions>
<self-uri content-type="pdf" xlink:href="khvi-15-05-1571893.pdf"></self-uri>
<abstract>
<title>ABSTRACT</title>
<p>The advent of engineered T cells as a form of immunotherapy marks the beginning of a new era in medicine, providing a transformative way to combat complex diseases such as cancer. Following FDA approval of CAR T cells directed against the CD19 protein for the treatment of acute lymphoblastic leukemia and diffuse large B cell lymphoma, CAR T cells are poised to enter mainstream oncology. Despite this success, a number of patients are unable to receive this therapy due to inadequate T cell numbers or rapid disease progression. Furthermore, lack of response to CAR T cell treatment is due in some cases to intrinsic autologous T cell defects and/or the inability of these cells to function optimally in a strongly immunosuppressive tumor microenvironment. We describe recent efforts to overcome these limitations using CRISPR/Cas9 technology, with the goal of enhancing potency and increasing the availability of CAR-based therapies. We further discuss issues related to the efficiency/scalability of CRISPR/Cas9-mediated genome editing in CAR T cells and safety considerations. By combining the tools of synthetic biology such as CARs and CRISPR/Cas9, we have an unprecedented opportunity to optimally program T cells and improve adoptive immunotherapy for most, if not all future patients.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>KEYWORDS</title>
<kwd>CAR T cell</kwd>
<kwd>CRISPR/Cas9</kwd>
<kwd>cancer immunotherapy</kwd>
<kwd>genome editing</kwd>
</kwd-group>
<counts>
<fig-count count="2"></fig-count>
<ref-count count="77"></ref-count>
<page-count count="7"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>